Cardiovascular diseases (CVDs) remain the leading cause of death globally, with elevated low-density lipoprotein cholesterol (LDL-C) being a major risk factor. Traditional cholesterol-lowering therapies, such as statins, have been effective but may not suffice for all patients, particularly those with familial hypercholesterolemia or statin intolerance. In recent years, PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) knockout has emerged as a groundbreaking strategy for profound and sustained LDL-C reduction.
PCSK9 is a protein that regulates LDL receptor (LDLR) degradation in the liver. Normally, LDLRs bind and remove LDL-C from circulation. However, PCSK9 binds to LDLRs, promoting their lysosomal degradation and reducing the liver’s ability to clear LDL-C. Elevated PCSK9 levels lead to higher LDL-C, while its inhibition or knockout enhances LDLR recycling, significantly lowering plasma cholesterol.
Several approaches have been developed to inhibit or eliminate PCSK9 activity:
Monoclonal Antibodies (e.g., Evolocumab, Alirocumab) – These injectable drugs block PCSK9, increasing LDLR availability. However, they require frequent administration.
Gene Silencing (siRNA, e.g., Inclisiran) – Small interfering RNA (siRNA) therapies reduce PCSK9 production, offering longer-lasting effects with biannual dosing.
CRISPR-Cas9 Gene Editing – Permanent PCSK9 knockout via CRISPR has shown promise in preclinical and early clinical trials, potentially offering a one-time cure for hypercholesterolemia.
Recent advances in CRISPR-Cas9 gene editing have enabled precise disruption of the PCSK9 gene in hepatocytes. Studies in animal models and early human trials (e.g., VERVE-101, a base-editing therapy) demonstrate:
>90% reduction in circulating PCSK9
Sustained LDL-C lowering (up to 60% decrease)
Potential lifelong protection against atherosclerosis
Unlike antibodies or siRNA, CRISPR-mediated knockout provides a permanent solution, eliminating the need for chronic medications.
Dramatic LDL-C reduction – Effective even in refractory hypercholesterolemia.
Reduced cardiovascular risk – Lower LDL-C correlates with decreased CVD events.
One-time treatment – CRISPR-based editing could eliminate lifelong drug dependence.
While promising, PCSK9 knockout raises several considerations:
Off-target effects – CRISPR may unintentionally edit other genomic regions.
Long-term safety – The consequences of lifelong PCSK9 absence require further study.
Ethical and accessibility issues – High costs and regulatory hurdles may limit widespread adoption.
Ongoing clinical trials (e.g., VERVE-101, NCT05398029) aim to validate the safety and efficacy of PCSK9 gene editing in humans. If successful, this approach could revolutionize cardiovascular medicine, offering a potential cure for inherited and severe hypercholesterolemia.
PCSK9 knockout represents a transformative strategy for cholesterol management, leveraging advanced gene-editing technologies to achieve unprecedented LDL-C reduction. While challenges remain, the potential for a single-treatment cure makes this one of the most exciting developments in cardiovascular therapeutics.
Cohen, J.C. et al. (2006). PCSK9 mutations and LDL cholesterol. Science.
Rothgangl, T. et al. (2021). In vivo adenine base editing of PCSK9 in nonhuman primates. Nature.
VERVE Therapeutics. (2023). VERVE-101 Clinical Trial Updates.
